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A BS TR AC T
BACKGROUND
The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the inci-
dence of major adverse cardiovascular events when administered at hospital admis-
sion to patients with ST-segment elevation myocardial infarction (STEMI). Whether 
prehospital administration of ticagrelor can improve coronary reperfusion and the 
clinical outcome is unknown.
METHODS
We conducted an international, multicenter, randomized, double-blind study involv-
ing 1862 patients with ongoing STEMI of less than 6 hours’ duration, comparing 
prehospital (in the ambulance) versus in-hospital (in the catheterization laboratory) 
treatment with ticagrelor. The coprimary end points were the proportion of patients 
who did not have a 70% or greater resolution of ST-segment elevation before percuta-
neous coronary intervention (PCI) and the proportion of patients who did not have 
Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-related artery at 
initial angiography. Secondary end points included the rates of major adverse cardio-
vascular events and definite stent thrombosis at 30 days.
RESULTS
The median time from randomization to angiography was 48 minutes, and the me-
dian time difference between the two treatment strategies was 31 minutes. The two 
coprimary end points did not differ significantly between the prehospital and in-
hospital groups. The absence of ST-segment elevation resolution of 70% or greater 
after PCI (a secondary end point) was reported for 42.5% and 47.5% of the patients, 
respectively. The rates of major adverse cardiovascular events did not differ signifi-
cantly between the two study groups. The rates of definite stent thrombosis were 
lower in the prehospital group than in the in-hospital group (0% vs. 0.8% in the first 
24 hours; 0.2% vs. 1.2% at 30 days). Rates of major bleeding events were low and 
virtually identical in the two groups, regardless of the bleeding definition used.
CONCLUSIONS
Prehospital administration of ticagrelor in patients with acute STEMI appeared to 
be safe but did not improve pre-PCI coronary reperfusion. (Funded by AstraZeneca; 
ATLANTIC ClinicalTrials.gov number, NCT01347580.)
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Effective antiplatelet therapy com-bining the inhibition of both thromboxane A2–dependent platelet aggregation and P2Y12 
receptors is necessary in patients undergoing per-
cutaneous coronary intervention (PCI), particu-
larly those with ST-segment elevation myocardial 
infarction (STEMI). Studies in this patient popu-
lation have shown that the more intense P2Y12-
receptor inhibition achieved with the use of pra-
sugrel, ticagrelor, or cangrelor, as compared with 
clopidogrel, is associated with better clinical out-
comes and a lower risk of stent thrombosis.1-5 The 
benefit was obtained with in-hospital administra-
tion of these drugs, and it is not known whether 
earlier administration would be as safe and pos-
sibly more effective.
The concept of prehospital administration of 
antiplatelet agents in primary PCI was first inves-
tigated with the glycoprotein IIb/IIIa inhibitor ab-
ciximab, which was associated with a higher rate 
of Thrombolysis in Myocardial Infarction (TIMI) 
flow grade 3 before primary PCI and lower rates 
of ischemic events, as compared with placebo.6 
Further studies confirmed the benefit of earlier 
administration of glycoprotein IIb/IIIa inhibitors 
in patients with STEMI, especially in those pre-
senting very soon after symptom onset.7-11 How-
ever, the benefit was less certain in patients at lower 
risk for ischemic events or presenting later.12,13
Various studies and meta-analyses suggested 
that pretreatment with clopidogrel in patients with 
STEMI could reduce the rate of ischemic events 
without excess bleeding,14-16 but its effectiveness 
may be limited by its slow onset of action and 
the variable response. In contrast, the new oral 
P2Y12-receptor antagonists inhibit platelet func-
tion in less than 1 hour, which is compatible 
with transfer times for primary PCI.17,18 Although 
some studies suggested that the full effect of 
prasugrel or ticagrelor on platelet function may 
take several hours in patients with STEMI,19-21 to 
our knowledge, these data have never been evalu-
ated in relation to clinical outcomes.
Ticagrelor is a direct-acting inhibitor of the 
platelet P2Y12 receptor with a rapid antiplatelet 
effect.17,22 It has been shown to reduce the rate of 
major cardiovascular events among patients with 
acute coronary syndromes, as compared with 
clopidogrel,23 and has the potential to improve 
coronary reperfusion and the prognosis for patients 
with STEMI treated with primary PCI.24 The aim 
of the ATLANTIC (Administration of Ticagrelor 
in the Cath Lab or in the Ambulance for New ST 
Elevation Myocardial Infarction to Open the Cor-
onary Artery) study was to evaluate whether 
early, in-ambulance administration of ticagrelor 
could safely improve coronary reperfusion in pa-
tients with STEMI transferred for primary PCI.
ME THODS
STUDY DESIGN AND PATIENTS
The ATLANTIC study was a phase 4, international, 
randomized, double-blind study.25 Patients were 
randomly assigned to receive either prehospital 
(in the ambulance) or in-hospital (in the catheter-
ization laboratory) treatment with ticagrelor, in 
addition to aspirin and standard care. The clini-
cal study protocol is available with the full text of 
this article at NEJM.org. The coordinating center 
was the Allies in Cardiovascular Trials Initiatives 
and Organized Networks (ACTION) Study Group 
at Pitié–Salpêtrière Hospital. The trial design and 
protocol were approved by the national regula-
tory authorities in all the participating countries 
and by the local ethics committee or institutional 
review board at each participating site. All the 
patients provided written informed consent.
Eligible patients, identified by ambulance per-
sonnel after STEMI had been diagnosed, had a 
symptom duration of more than 30 minutes but 
less than 6 hours, with an expected time from 
the qualifying electrocardiogram (ECG) to the 
first balloon inflation of less than 120 minutes. 
Randomization and the first loading dose of the 
study drug took place immediately after the di-
agnostic ECG and before the administration of a 
loading dose of any P2Y12-receptor antagonist. Pa-
tients were then transferred to a hospital to un-
dergo coronary angiography, with or without PCI.
STUDY PROCEDURES
In the prehospital group, patients received a 180-mg 
loading dose of ticagrelor before transfer and then 
a matching placebo in the catheterization labora-
tory. Patients in the in-hospital group received a 
placebo before transfer and then a 180-mg load-
ing dose of ticagrelor in the catheterization labo-
ratory. All the patients subsequently received ti-
cagrelor at a dose of 90 mg twice daily for 30 days, 
with a recommendation that treatment be con-
tinued for a total of 12 months. In-ambulance 
use of glycoprotein IIb/IIIa inhibitors was discour-
aged but was left to the physician’s discretion. 
In-laboratory use of glycoprotein IIb/IIIa inhibi-
tors after angiography had to be identified as either 
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a strategy of choice or a bailout treatment during 
PCI. A pharmacodynamic substudy was conducted 
at five participating centers, the main end point 
of which was the result of a phosphorylation as-
say for measuring the platelet-reactivity index of 
a vasodilator-stimulated phosphoprotein at the 
start of catheterization (before PCI).25
STUDY END POINTS
The coprimary end points were the proportion of 
patients who did not have 70% or greater resolu-
tion of ST-segment elevation before PCI and the 
proportion of patients who did not meet the cri-
teria for TIMI flow grade 3 in the infarct-related 
artery at angiography before PCI. Prespecified sec-
ondary end points included the composite of death, 
myocardial infarction, stent thrombosis, stroke, or 
urgent revascularization at 30 days; definite stent 
thrombosis at 30 days; thrombotic bailout with 
glycoprotein IIb/IIIa inhibitors; TIMI flow grade 3 
at the end of the procedure; and complete (≥70%) 
resolution of ST-segment elevation at 60 minutes 
after PCI.
Safety end points included major bleeding, 
life-threatening bleeding, and minor bleeding (ex-
cluding bleeding related to coronary-artery by-
pass grafting) within the first 48 hours and over 
the 30-day treatment period, evaluated with the 
use of PLATO (Study of Platelet Inhibition and 
Patient Outcomes), TIMI, STEEPLE (Safety and 
Efficacy of Enoxaparin in Percutaneous Coronary 
Intervention Patients), ISTH (International Society 
on Thrombosis and Haemostasis), GUSTO (Global 
Utilization of Streptokinase and Tissue Plasmino-
gren Activator for Occluded Coronary Arteries), 
and BARC (Bleeding Academic Research Consor-
tium) criteria.25
Centralized, blinded reviews of angiographic 
data and ECG recordings were conducted by Car-
dialysis Core Laboratory services (Rotterdam, the 
Netherlands) and eResearch Technology (ERT; 
Peterborough, United Kingdom), respectively. An 
independent adjudication committee, whose mem-
bers were unaware of the treatment assignments, 
reviewed the clinical end points, except deaths and 
minimal bleeding events (see the Supplementary 
Appendix, available at NEJM.org).
STUDY OVERSIGHT AND FUNDING
The executive and steering committees (see the 
Supplementary Appendix) oversaw the conduct of 
the trial and data analysis, in collaboration with 
representatives of the study sponsor (AstraZeneca). 
The trial was monitored by an independent data 
and safety monitoring board (see the Supplemen-
tary Appendix).
Data were collected and analyzed by World-
wide Clinical Trials (London) according to the 
protocol and the predefined statistical analysis 
plan. The chair of the executive committee (the 
first author) had unrestricted access to the data 
after the database was locked, and statistical 
analyses were performed independently by one 
of the academic authors, who is a statistician for 
the ACTION study group. The first author pre-
pared the first draft of the manuscript; all the 
authors revised the manuscript and made the 
decision to submit it for publication. All the au-
thors assume responsibility for the accuracy and 
completeness of the data and analyses reported 
and for the fidelity of the study to the protocol. 
Medical-writing support, funded by AstraZeneca, 
was provided by Prime Medica.
STATISTICAL ANALYSIS
We calculated that the study would have 80% pow-
er to detect a difference of 6 percentage points 
(40% relative difference) between the two groups 
in the complete resolution of ST-segment elevation, 
assuming a 15% rate of complete resolution in 
the control group (i.e., patients who received the 
initial loading dose of ticagrelor in the hospital).24 
The study was also adequately powered to assess 
differences regarding TIMI flow before PCI.25
Efficacy analyses were performed in the modi-
fied intention-to-treat population, defined as all 
the patients who underwent randomization and 
received at least one dose of the study drug. Pa-
tients with missing data for either ST-segment 
elevation or TIMI flow grade were excluded from 
the analysis of the two coprimary end points. For 
each end point, the treatment groups were com-
pared with the use of a logistic-regression model 
with treatment as an exploratory variable. A Holm 
procedure to correct for multiple comparisons, 
which included the adjustment of significance 
level and sequential testing, was used to control 
the overall type I error rate of 5% in testing the 
two coprimary end points.
Subgroup analyses to evaluate variations in 
treatment effect were performed with the use of 
the logistic-regression model and with terms for 
treatment, subgroup, and interaction of treatment 
with subgroup. P values were not adjusted for 
these analyses.
Secondary end points (clinical end points, reso-
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1862 Provided informed consent
and underwent randomization
1875 Patients were enrolled
909 Were assigned to prehospital ticagrelor
and in-hospital placebo
953 Were assigned to prehospital placebo
and in-hospital ticagrelor
909 Were included
in full analysis
908 Were included
in safety analysis
906 Were included
in modified intention-
to-treat analysis
844 Completed study
65 Discontinued
study
13 Withdrew
10 Did not fulfill
eligibility criteria
30 Died
3 Were lost to
follow-up
9 Had other
reasons
897 Completed study
56 Discontinued
study
23 Withdrew
7 Did not fulfill
eligibility criteria
19 Died
1 Was lost to
follow-up
6 Had other
reasons
824 Could be evaluated
for TIMI flow grade
82 Had missing
pre-PCI TIMI flow
grade
774 Could be evaluated
for ST-segment
resolution
8 Had missing 
prehospital ECG
112 Had missing 
pre-PCI ECG
18 Had no clinically
significant
ST-segment eleva-
tion prehospital
953 Were included
in full analysis
950 Were included
in safety analysis
952 Were included
in modified intention-
to-treat analysis
856 Could be evaluated
for TIMI flow grade
96 Had missing 
pre-PCI TIMI flow
grade
824 Could be evaluated
for ST-segment
resolution
8 Had missing
prehospital ECG
100 Had missing 
pre-PCI ECG
33 Had no clinically
significant
ST-segment eleva-
tion prehospital
Figure 1. Study Populations and Reasons for Discontinuation.
Reasons for exclusion from the modified intention-to-treat population included nonreceipt of study medication (in three patients in the 
prehospital group and in one in the in-hospital group). In the safety analysis, data were analyzed according to the study medication 
actually received. Reasons for exclusion from the safety population included nonreceipt of study medication as well as receipt of study 
medication in an incorrect order (i.e., not according to the randomized assignment; in one patient in the prehospital group and in three 
in the in-hospital group). Data from patients who could not be evaluated for TIMI flow grade or for resolution of ST-segment elevation 
may be reported in more than one category of missing data.
lution of ST-segment elevation or TIMI flow at the 
end of the procedure, and thrombotic bailout with 
glycoprotein IIb/IIIa inhibitors) were examined 
with the use of an analysis identical to that de-
scribed for the coprimary end points. Kaplan–
Meier estimates of clinical end points were also 
calculated for the first 30 days after the first 
dose. Since no prespecified hypothesis was made, 
statistical testing of all secondary efficacy vari-
ables, including the clinical end points, was con-
sidered to be exploratory, and no hierarchical rule 
for tests or adjustment was used.
The safety analysis included all the patients 
who received at least one dose of the study 
drug. Adjudicated bleeding events were sum-
marized separately, according to the protocol 
definition (PLATO criteria) and other prespeci-
fied definitions.
R ESULT S
PATIENTS AND PROCEDURES
Between September 12, 2011, and October 3, 
2013, a total of 1875 patients were enrolled in the 
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ATLANTIC study, of whom 1862 provided writ-
ten informed consent and were randomly assigned 
to either prehospital ticagrelor (909 patients) or 
in-hospital ticagrelor (953 patients). Randomiza-
tion was performed by 102 ambulance services, 
followed by transfer to 112 PCI centers in 13 
countries (Table S1 in the Supplementary Appen-
dix). Reasons for discontinuation and for exclu-
sion from the analyses are shown in Figure 1.
The characteristics of the patients at baseline 
were well balanced between the two groups, 
with a numerically small, nonsignificant imbal-
ance with respect to a TIMI risk score of more 
than 6 (Table 1, and Table S2 in the Supplementary 
Appendix). The first medical contact was in the 
ambulance for more than 75% of the patients; 
the first medical contact for the remaining pa-
tients was in an emergency department, before 
ambulance transfer. Coronary angiography was 
performed primarily by means of radial access 
Table 1. Demographic Characteristics and Treatment of the Patients at Baseline.*
Characteristic
Prehospital Ticagrelor
(N = 909)
In-Hospital Ticagrelor
(N = 953)
Age
Mean age — yr 60.6±12.4 61.0±12.5
≥75 yr — no. (%) 144 (15.8) 160 (16.8)
Female sex — no. (%) 173 (19.0) 196 (20.6)
Body weight — kg 80.4±15.9 79.7±15.6
BMI ≥30 — no. (%)† 177 (19.5) 178 (18.7)
Diabetes mellitus — no. (%) 115 (12.7) 138 (14.5)
TIMI risk score — no. (%)‡
0–2 552 (60.7) 573 (60.1)
3–6 337 (37.1) 365 (38.3)
>6 20 (2.2) 15 (1.6)
Killip class I — no. (%) 819 (90.1) 862 (90.5)
First medical contact — no. (%)§
In ambulance 689 (75.8) 723 (75.9)
In emergency department before ambulance transfer 220 (24.2) 229 (24.0)
Procedures for index event
Coronary angiography — no. (%) 890 (97.9) 937 (98.3)
Femoral access — no./total no. (%) 280/890 (31.5) 309/937 (33.0)
Radial access — no./total no. (%) 604/890 (67.9) 625/937 (66.7)
Missing data — no./total no. (%) 6/890 (0.7) 3/937 (0.3)
Thromboaspiration — no. (%) 471 (51.8) 470 (49.3)
PCI — no. (%) 800 (88.0) 830 (87.1)
With stent¶ 760 (83.6) 776 (81.4)
Drug-eluting stent 467 (51.4) 479 (50.3)
Bare-metal stent 305 (33.6) 312 (32.7)
Without stent 40 (4.4) 54 (5.7)
CABG — no. (%) 10 (1.1) 15 (1.6)
No PCI or CABG — no. (%) 99 (10.9) 108 (11.3)
Study medication — no. (%)
First loading dose 905 (99.6) 952 (99.9)
Second loading dose 864 (95.0) 908 (95.3)
Maintenance dose 784 (86.2) 809 (84.9)
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Table 1. (Continued.)
Characteristic
Prehospital Ticagrelor
(N = 909)
In-Hospital Ticagrelor
(N = 953)
Aspirin — no. (%)
Any use 898 (98.8) 938 (98.4)
Maintenance dose 843 (92.7) 880 (92.3)
Other antithrombotic medication for index event — no. (%)
Glycoprotein IIb/IIIa inhibitor before PCI‖ 274 (30.1) 259 (27.2)
Intravenous anticoagulant during hospitalization 791 (87.0) 851 (89.3)
Heparin 607 (66.8) 654 (68.6)
Enoxaparin 247 (27.2) 253 (26.5)
Bivalirudin 175 (19.3) 190 (19.9)
Fondaparinux 51 (5.6) 63 (6.6)
Combination therapy** 274 (30.1) 286 (30.0)
* Plus–minus values are means ±SD. There were no significant between-group differences in the baseline characteris-
tics listed here. For further details, see Table S2 in the Supplementary Appendix. CABG denotes coronary-artery by-
pass grafting, and PCI percutaneous coronary intervention.
† The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
‡ Thrombolysis in Myocardial Infarction (TIMI) risk scores assess the prognosis for patients with acute coronary syn-
dromes on a scale from 0 to 14, with higher scores indicating greater risk.
§ The location of care at the time of randomization was unknown for one patient in the in-hospital group. First medical 
contact was defined as occurring either in the ambulance (primary transfer to an appropriate hospital setting) or in 
an emergency department before ambulance transfer (secondary transfer to an appropriate hospital setting).
¶ Patients may have received more than one type of stent.
‖ Data on glycoprotein IIb/IIIa inhibitor use (before and after PCI) were missing for two patients in the prehospital group.
** Combination therapy was defined as a sequence of prescriptions for different anticoagulants, with changes in antico-
agulant use during the hospitalization phase.
(in 67.3% of the patients who underwent coro-
nary angiography), and PCI was performed in 
87.5% of the patients (Table 1).
The median times from symptom onset to 
STEMI diagnosis, from randomization to angi-
ography, and between the two loading doses 
(i.e., prehospital vs. in-hospital), were 73, 48, and 
31 minutes, respectively (Fig. S1 in the Supple-
mentary Appendix). The first and second load-
ing doses of study medication were administered 
to more than 99% and 95% of the patients, re-
spectively, and nearly 99% received at least one 
dose of aspirin (Table 1). The majority of pa-
tients with STEMI received maintenance treat-
ment with ticagrelor (85.6% of patients) and as-
pirin (92.5%). Just over one third of patients 
received a glycoprotein IIb/IIIa inhibitor.
EFFICACY
Platelet reactivity was reduced significantly and 
progressively after the administration of tica-
grelor in both study groups in the pharmacody-
namic substudy, which included 37 patients. There 
was no significant difference between prehospi-
tal and in-hospital administration of ticagrelor at 
any time point, with the maximum numerical 
difference between the treatment groups being 
observed 1 hour after PCI (Fig. S2 and S3 in the 
Supplementary Appendix).
There was no significant difference between 
the prehospital group and the in-hospital group in 
terms of the proportion of patients who did not 
have a 70% or greater resolution of ST-segment 
elevation before PCI (odds ratio with prehospital 
vs. in-hospital administration of the loading dose 
of ticagrelor, 0.93; 95% confidence interval [CI], 
0.69 to 1.25; P = 0.63) and the proportion of pa-
tients who did not have a TIMI flow of grade 3 
in the infarct-related artery at initial angiography 
(odds ratio, 0.97; 95% CI, 0.75 to 1.25; P = 0.82) 
(Table 2). The absence of 70% or greater resolu-
tion of ST-segment elevation 1 hour after PCI was 
reported for 42.5% of patients in the prehospital 
group and 47.5% of those in the in-hospital 
group (P = 0.055), and the absence of TIMI flow 
grade 3 in the culprit artery was reported for 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on January 13, 2015. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;11 nejm.org september 11, 20141022
17.8% and 19.6% of the patients, respectively 
(P = 0.34). The results were consistent across quar-
tiles of time from the first loading dose to the 
ECG or angiogram obtained before PCI, corre-
sponding to different transfer times (data not 
shown). The results were also consistent for both 
coprimary end points across prespecified sub-
groups, except for the subgroup of patients in 
whom morphine was administered (Fig. S4 in the 
Supplementary Appendix). The primary end 
point of ST-segment resolution was significantly 
improved with prehospital administration of ti-
cagrelor in patients not receiving morphine 
(P = 0.005 for interaction).
There were no significant differences between 
the two groups for the composite end point of 
death, myocardial infarction, stroke, urgent cor-
onary revascularization, or stent thrombosis 
(Fig. S5 in the Supplementary Appendix). How-
ever, definite stent thrombosis was reduced in 
the prehospital group both at 24 hours (0 of 906 
patients [0%] in the prehospital group vs. 8 of 
952 [0.8%] in the in-hospital group, P = 0.008 by 
Fisher’s exact test) and at 30 days (2 of 906 
[0.2%] vs. 11 of 952 [1.2%], P = 0.02) (Fig. 2 and 
Table 3). There was no clear relationship between 
type of anticoagulation and the occurrence of 
stent thrombosis (Table S3 in the Supplementary 
Appendix).
A total of 30 patients (3.3%) in the prehospi-
tal group and 19 (2.0%) in the in-hospital group 
died (P = 0.08). The most common causes of death 
were cardiogenic shock, cardiac arrest, mechan-
ical complication, and heart failure (Table S4 in 
the Supplementary Appendix).
SAFETY
Rates of bleeding events that were not related to 
coronary-artery bypass grafting were low during 
the first 48 hours after the initial dose and from 
Table 2. Coprimary Efficacy End Points and Related Secondary End Points in the Modified Intention-to-Treat Population.*
End Point
Prehospital 
Ticagrelor
(N = 906)
In-Hospital 
Ticagrelor
(N = 952)
Odds Ratio
(95% CI)† P Value†
Difference
(95% CI)‡
no./no. of patients who could be 
evaluated (%)
Coprimary end points
Absence of ST-segment elevation resolu-
tion ≥70% before PCI
672/774 (86.8) 722/824 (87.6) 0.93 (0.69 to 1.25) 0.63 –0.008 (–0.041 to 0.025)
Absence of TIMI flow grade 3 in infarct-
related artery at initial angiography
681/824 (82.6) 711/856 (83.1) 0.97 (0.75 to 1.25) 0.82 –0.004 (–0.040 to 0.032)
Met one or both coprimary end points
Both 541/744 (72.7) 571/777 (73.5) 0.96 (0.77 to 1.21) 0.73 –0.008 (–0.052 to 0.037)
One or both 677/719 (94.2) 710/751 (94.5) 0.93 (0.60 to 1.45) 0.75 –0.004 (–0.027 to 0.020)
Secondary end points
Absence of ST-segment elevation resolu-
tion ≥70% after PCI
303/713 (42.5) 353/743 (47.5) 0.82 (0.66 to 1.004) 0.05 –0.050 (–0.101 to 0.001)
Absence of TIMI flow grade 3 in infarct 
related artery after PCI
135/760 (17.8) 154/784 (19.6) 0.88 (0.68 to 1.14) 0.34 –0.019 (–0.058 to 0.020)
Met one or both secondary end points
Both 73/763 (9.6) 87/775 (11.2) 0.84 (0.60 to 1.16) 0.29 –0.017 (–0.047 to 0.014)
One or both 339/684 (49.6) 371/703 (52.8) 0.88 (0.71 to 1.09) 0.23 –0.032 (–0.085 to 0.020)
* Data include the total number of patients who had data that could be evaluated. Data were missing as follows: TIMI flow grade for 178 pa-
tients (82 patients in the prehospital group and 96 in the in-hospital group), prehospital ST-segment elevation for 16 (8 in each treatment 
group), and pre-PCI ST-segment elevation for 212 (112 in the prehospital group and 100 in the in-hospital group). Before arrival at the hos-
pital, 51 patients had no clinically significant ST elevation and therefore could not be evaluated for resolution of ST-segment elevation  
(18 patients in the prehospital group and 33 in the in-hospital group). ST-segment resolution was calculated as the combination of two elec-
trocardiographic (ECG) variables (ST segment at index ECG and ST segment before PCI).
† The odds ratios for the prehospital group versus the in-hospital group, two-sided 95% confidence intervals, and P values were calculated 
from a logistic-regression model, with treatment as the only explanatory variable.
‡ The difference in binomial proportions was calculated as the proportion in the prehospital group minus the proportion in the in-hospital group.
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Figure 2. Definite Stent Thrombosis up to 30 Days after Ticagrelor 
Administration in the Modified Intention-to-Treat Population.
48 hours through 30 days, and the rates did not 
differ significantly between the two study groups 
(Table 3). The results were consistent across all 
the definitions and types of bleeding adjudicated 
by the clinical end-point committee (Table S5 in 
the Supplementary Appendix). There was no sig-
nificant difference in the rates of bleeding events 
between the two study groups among the 11.1% 
of patients who did not undergo revasculariza-
tion or among the 8.6% of patients who did not 
have a final diagnosis of STEMI. There was no 
imbalance between the two treatment groups in 
terms of serious adverse events.
DISCUSSION
Prehospital treatment of ongoing STEMI with fi-
brinolytic agents or glycoprotein IIb/IIIa inhibi-
tors has been associated with improved coronary 
reperfusion and outcomes.6,8,26-29 The present 
study shows that the administration of the po-
tent P2Y12-receptor antagonist ticagrelor shortly 
before PCI does not improve reperfusion of the 
culprit artery before the procedure but is safe and 
may prevent postprocedural acute stent throm-
bosis. The observed preventive benefit is consis-
tent with pharmacodynamic and ECG findings 
suggesting that the maximal effect of prehospi-
tal administration of ticagrelor occurs after the 
end of the procedure.
Pretreatment (i.e., before coronary angiogra-
phy) with glycoprotein IIb/IIIa inhibitors or 
P2Y12-receptor antagonists in patients with non–
ST-segment elevation (NSTE) acute coronary 
syndromes has been associated with excess bleed-
ing, without a reduction in ischemic complica-
tions,18,30,31 leading to guideline recommenda-
tions against the use of these agents in such 
patients.32,33 There is limited information on 
pretreatment with clopidogrel in patients with 
STEMI undergoing PCI, but the available data 
suggest that there is no safety issue and that the 
rate of major adverse cardiovascular events may 
be reduced.14,15 The ATLANTIC study shows that 
the early administration of ticagrelor in patients 
with STEMI is safe, regardless of the definition 
of bleeding used. This favorable safety profile 
may be related to the high likelihood of both 
confirmation of the diagnosis of STEMI and 
treatment with PCI and placement of a stent; in 
contrast, the diagnosis of NSTE acute coronary 
syndrome in patients presenting with transient 
chest pain is often not confirmed, and PCI is not 
performed in 30 to 60% of such patients.34,35
The rate of stent thrombosis was reduced with 
prasugrel or ticagrelor in the STEMI cohorts in 
the pivotal trials comparing these agents with 
clopidogrel1,36; whether earlier administration of 
these drugs could further reduce the risk was 
unknown. In this study, all the stent-thrombosis 
events within the first 24 hours occurred in the 
in-hospital group, and the difference remained 
significant in favor of prehospital administra-
tion of ticagrelor for up to 30 days. Although our 
platelet-reactivity results lack statistical power, 
the maximal difference in platelet inhibition oc-
curred concomitantly with the reduction of stent 
thrombosis, the findings being supportive of one 
another. Stent thrombosis has been under scru-
tiny, and the excess of early stent-thrombosis 
events observed consistently across trials with 
bivalirudin37-39 has been seen largely as a reason 
for limiting its use. In our study, the rate of defi-
nite stent thrombosis was reduced without a safety 
trade-off. Although prespecified, stent thrombosis 
was a secondary end point among neutral study 
results; therefore, this finding should not be in-
terpreted as definitive.
Mortality was reduced with ticagrelor, as 
compared with clopidogrel, in the large PLATO 
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trial.23 In the ATLANTIC trial, mortality was low 
and there was a nonsignificant numerical excess 
of deaths in the prehospital group. Almost all the 
deaths were due to cardiogenic shock, cardiac 
arrest, or cardiac rupture rather than to bleeding 
or ischemic events. This finding may reflect the 
fact that ambulance crews did not exclude the 
sickest patients from the study, and we cannot 
rule out an imbalance between the two study 
groups in terms of the severity of the presenting 
event (e.g., a higher TIMI risk score in the pre-
hospital group).
Our study has limitations inherent in the 
sample size and the short intervals between ad-
ministration of the study drug and reperfusion. 
There is consistency across the data on pharma-
codynamics, ST-segment resolution, and TIMI 
flow grade, which suggests that most of the 
drug effect occurred after PCI. The time to PCI 
in our study was extremely short in both groups, 
indicating excellent practice, but this may have 
blunted the drug effect and may not reflect rou-
tine practice. Another potential limitation is re-
lated to the delayed absorption of orally admin-
istered P2Y12-receptor antagonists.19-21 The onset 
of action may have been delayed further by mor-
phine coadministration in half the study popula-
tion.21,40 Patients who did not receive morphine 
had a significant improvement in the ECG-based 
primary end point, with a significant P value for 
interaction between morphine use and time of 
ticagrelor administration. The extent to which 
this interaction may have affected our results re-
mains unknown at this stage.
In conclusion, prehospital administration of 
ticagrelor a short time before PCI in patients pre-
senting with ongoing STEMI appeared to be safe 
but did not improve pre-PCI coronary reperfusion.
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